NGcGM3 Ganglioside: A Privileged Target for Cancer Vaccines

Active specific immunotherapy is a promising field in cancer research. N-glycolyl (NGc) gangliosides, and particularly NGcGM3, have received attention as a privileged target for cancer therapy. Many clinical trials have been performed with the anti-NGc-containing gangliosides anti-idiotype monoclona...

Full description

Saved in:
Bibliographic Details
Main Authors: Luis E. Fernandez, Mariano R. Gabri, Marcelo D. Guthmann, Roberto E. Gomez, Silvia Gold, Leonardo Fainboim, Daniel E. Gomez, Daniel F. Alonso
Format: Article
Language:English
Published: Wiley 2010-01-01
Series:Clinical and Developmental Immunology
Online Access:http://dx.doi.org/10.1155/2010/814397
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Active specific immunotherapy is a promising field in cancer research. N-glycolyl (NGc) gangliosides, and particularly NGcGM3, have received attention as a privileged target for cancer therapy. Many clinical trials have been performed with the anti-NGc-containing gangliosides anti-idiotype monoclonal antibody racotumomab (formerly known as 1E10) and the conjugated NGcGM3/VSSP vaccine for immunotherapy of melanoma, breast, and lung cancer. The present paper examines the role of NGc-gangliosides in tumor biology as well as the available preclinical and clinical data on these vaccine products. A brief discussion on the relevance of prioritization of cancer antigens in vaccine development is also included.
ISSN:1740-2522
1740-2530